Keymed Biosciences Unveils Breakthrough Findings on CM336 in New England Journal of Medicine Keymed Biosciences has announced groundbreaking results from a clinical trial of CM336, targeting autoimmune hemolytic anemia, published in NEJM.

Keymed Biosciences Unveils Breakthrough Findings on CM336 in New England Journal of Medicine #None #Chengdu #Keymed_Biosciences #CM336 #Autoimmune_Hemolytic_Anemia

Keymed Biosciences Unveils Promising Clinical Trial Results of CM336 for Autoimmune Hemolytic Anemia Keymed Biosciences has announced groundbreaking outcomes from its clinical trial for CM336 treatment in autoimmune hemolytic anemia, highlighting significant patient remission.

Keymed Biosciences Unveils Promising Clinical Trial Results of CM336 for Autoimmune Hemolytic Anemia #China #Chengdu #Keymed_Biosciences #CM336 #Autoimmune_Hemolytic_Anemia